These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21684381)

  • 41. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
    Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
    Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.
    Lynge E; Antilla A; Arbyn M; Segnan N; Ronco G
    Eur J Cancer; 2009 Oct; 45(15):2714-21. PubMed ID: 19695870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lower Incidence of Cervical Intraepithelial Neoplasia among Young Women with Human Papillomavirus Vaccination in Miyagi, Japan.
    Ozawa N; Ito K; Tase T; Shibuya D; Metoki H; Yaegashi N
    Tohoku J Exp Med; 2017 Dec; 243(4):329-334. PubMed ID: 29269635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
    Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
    El-Zein M; Richardson L; Franco EL
    J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
    Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
    J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
    McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
    Brotherton JM; Mullins RM
    Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
    Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
    Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
    Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
    Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
    Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The difference in the effectiveness of human papillomavirus vaccine based on smoking status.
    Hikari T; Honda A; Hashiguchi M; Okuma R; Kurihara M; Fukuda A; Okuma E; Nakao Y; Yokoyama M
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1859-1866. PubMed ID: 35599387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group
    N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
    Ault KA; Joura EA; Kjaer SK; Iversen OE; Wheeler CM; Perez G; Brown DR; Koutsky LA; Garland SM; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Majewski S; Muñoz N; Sings HL; Harkins K; Rutkowski MA; Haupt RM; Garner EI;
    Int J Cancer; 2011 Mar; 128(6):1344-53. PubMed ID: 20949623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
    Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?
    Saleem A; Tristram A; Fiander A; Hibbitts S
    Minerva Med; 2009 Dec; 100(6):503-23. PubMed ID: 20010484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.